2012
DOI: 10.1002/ccd.23403
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: The use of Impella 2.5 in high-risk PCI appeared feasible and safe in the real-world setting. The utilization of the Impella 2.5 was successful, resulting in favorable short- and midterm angiographic, procedural and clinical outcomes.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

5
85
2
2

Year Published

2012
2012
2017
2017

Publication Types

Select...
7

Relationship

5
2

Authors

Journals

citations
Cited by 132 publications
(94 citation statements)
references
References 27 publications
5
85
2
2
Order By: Relevance
“…Similarly, we did not observe any aortic or mitral valve dysfunction or left ventricular injury, which confirms the safety profile of the Impella 2.5 device with respect to ventricular and valve function and integrity, consistent with previous reports. 7,12,17,18 Analysis of the Kaplan-Meier event curves suggests that the use of a 30-day end point is not sufficient in this population. Other investigations of PCI in severely compromised patients such as the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial 19 and the BCIS-1 study 16 found that event curves continue to diverge over time.…”
Section: Discussionmentioning
confidence: 99%
“…Similarly, we did not observe any aortic or mitral valve dysfunction or left ventricular injury, which confirms the safety profile of the Impella 2.5 device with respect to ventricular and valve function and integrity, consistent with previous reports. 7,12,17,18 Analysis of the Kaplan-Meier event curves suggests that the use of a 30-day end point is not sufficient in this population. Other investigations of PCI in severely compromised patients such as the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock (SHOCK) trial 19 and the BCIS-1 study 16 found that event curves continue to diverge over time.…”
Section: Discussionmentioning
confidence: 99%
“…93 A large observational study of the Impella 2.5 device in HR-PCI has been published. 94 Most patients were extremely high risk, including inoperable patients with a high prevalence of chronic kidney disease, prior coronary artery bypass grafting, and severe LV dysfunction, as well as a high prevalence of NYHA class IIIdIV heart failure. Despite these risk factors, procedural success was high with a 90% success rate with multi-vessel revascularization and 8% rate of 30-day major adverse cardiac events.…”
Section: Percutaneous Mechanical Circulatory Supportmentioning
confidence: 99%
“…Suggested Indications for Percutaneous MCS Particularly in patients with severe LV dysfunction (EF !20e30%) and complex coronary artery disease involving a large territory (sole-remaining vessel, left main or three vessel disease) 94,95,98. High-risk or complex ablation of ventricular tachycardia Similar to HR-PCI, complex VT ablation can be made feasible with percutaneous support.…”
mentioning
confidence: 98%
“…A large observational study of the Impella 2.5 device in HR-PCI has been published [94]. Most patients were extremely high risk, including inoperable patients with a high prevalence of chronic kidney disease, prior coronary artery bypass grafting, and severe LV dysfunction, as well as a high prevalence of NYHA class III-IV heart failure.…”
Section: Percutaneous Mechanical Circulatory Supportmentioning
confidence: 99%
“…For recurrent, refractory, ventricular arrhythmias, ECMO may be required for biventricular failure. Prophylactic use for high risk PCI Particularly in patients with severe LV dysfunction (EF <20-30%) and complex coronary artery disease involving a large territory (sole-remaining vessel, left main or three vessel disease) [94,95,98]. High-risk or complex ablation of ventricular tachycardia Similar to HR-PCI, complex VT ablation can be made feasible with percutaneous support.…”
Section: Refractory Arrhythmiasmentioning
confidence: 99%